HERNEXEOS product image Product image This press release is not intended for UK media HERNEXEOS® (zongertinib tablets) ...

Cancer treatment can take a profound financial toll, and new research shows the damage does not stop at the bank account. Nearly half of patients experience significant "financial toxicity," and that ...

Cancer treatment can take a profound financial toll, and new research shows the damage does not stop at the bank account.

Cancer treatment can take a profound financial toll, and new research shows the damage does not stop at the bank account.

The FDA granted zongertinib Breakthrough Therapy Designation for patients with HER2 (ERBB2)-mutant advanced NSCLC as an initial treatment. The FDA also awarded a Commissioner's National Priority ...

A study published today in the journal Science reveals how jumping fragments of human DNA, a type of genetic parasite, ...

This press release is not intended for UK media HERNEXEOS (zongertinib tablets) approved based on an objective response rate of 76% (N=72) as demonstrated in the Beamion LUNG-1 clinical trial1 Acceler ...

A study published in the journal Science reveals how jumping fragments of human DNA, a type of genetic parasite, destabilize the cancer genome. Unstable genomes are a fertile playground for cancer ...

US FDA grants full approval to Pfizer’s Braftovi combination regimen in first-line metastatic colorectal cancer: New York Thursday, February 26, 2026, 12:00 Hrs [IST] Pfizer Inc ...

Total revenue of $68.7 million in 4Q25 and $172.4 million in FY2025 – – Revuforj® (revumenib) net revenue of $44.2 million in 4Q25, a 38% increase vs 3Q25, and $124.8 million in FY2025 – – Niktimvo™ ...

The "Head and Neck Cancer Therapeutics Market -- Growth, Share, Opportunities & Competitive Analysis, 2024 -- 2032" report has been added to the offering of Credence Research Inc. The global head and ...

These 11 expert-backed exercises can improve mobility, balance, and range of motion after 50—helping you stay strong and independent.